Document is current
Any future updates will be listed below
-
Authors
Cabana-Domínguez, Judit https://orcid.org/0000-0002-4732-7284
Llonga, Natalia https://orcid.org/0000-0003-4325-6201
Arribas, Lorena
Alemany, Silvia https://orcid.org/0000-0002-7925-6767
Vilar-Ribó, Laura https://orcid.org/0000-0001-8758-523X
Demontis, Ditte https://orcid.org/0000-0001-9124-2766
Fadeuilhe, Christian
Corrales, Montse
Richarte, Vanesa
Børglum, Anders D. https://orcid.org/0000-0001-8627-7219
Ramos-Quiroga, Josep Antoni https://orcid.org/0000-0003-1622-0350
Soler Artigas, María https://orcid.org/0000-0002-3213-1107
Ribasés, Marta https://orcid.org/0000-0003-1039-1116
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CP22/00026, P19/01224, PI20/00041, PI22/00464, FI18/00285, CP22/00128)
Novo Nordisk Fonden (NNF20OC0065561)
Lundbeckfonden (R344-2020-1060)
- License Information
-
More Information
Article History
Received: 7 February 2023
Revised: 17 July 2023
Accepted: 21 July 2023
First Online: 3 August 2023
Competing interests
: JARQ was on the speakers’ bureau and/or acted as consultant for Biogen, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubió. CF and VR have received fees to give talks for Shire/Takeda and Rubió. All other authors declare no biomedical financial interests or conflicts of interest.
